Background Osteoporosis is an abnormal reduction in bone mass and bone deterioration
leading to increased fracture risk. Risedronate belongs to the bisphosphonate class of drugs …

Background This position paper addresses the prevention of bisphosphonate-associated
osteonecrosis (BON) and the management of care of patients with cancer and/or …

Bisphosphonates are a synthetic class of pyrophosphate analogues that are powerful
inhibitors of bone resorption which are commonly used as a medication for the prevention …

The potential for brief periods of low‐magnitude, high‐frequency mechanical signals to
enhance the musculoskeletal system was evaluated in young women with low BMD. Twelve …

The incidences of osteoporosis and renal insufficiency increase with age. We studied the
influence of renal function on the safety and efficacy of risedronate 5 mg daily in osteoporotic …

A critical need exists for efficient, measurable systems of disease management that
reconcile conflicts between socioeconomic responsibility and patient welfare. Clinical …

OBJECTIVE: To review the literature concerning the history, development, and therapeutic
uses of bisphosphonates. DATA SOURCES: English-language articles were identified …

Objective: To review the effect of risedronate on bone density and fractures in
postmenopausal women. Data Sources: We searched MEDLINE from 1966 to the end of …

Bisphosphonate drugs for treating osteoporosis are excreted by the kidney. However, many
of the major trials on efficacy and safety of the bisphophonates for treating osteoporosis …

Objective: To describe and evaluate the effectiveness of oral and dental prevention
strategies for cancer patients who were about to begin bisphosphonate (BP) intravenous …